World Health Organization (WHO) said on Saturday that it was discontinuing its trials of the malaria drug hydroxychloroquine and combination HIV drug lopinavir/ritonavir in hospitalized patients with COVID-19 after they failed to reduce mortality.
Global trial of hydroxychloroquine as coronavirus treatment to resume “These interim trial results show that hydroxychloroquine and lopinavir/ritonavir produce little or no reduction in the mortality of hospitalized COVID-19 patients when compared to standard of care.
Solidarity trial investigators will interrupt the trials with immediate effect,” the WHO said in a statement, referring to large multi-country trials that the agency is leading.The U.N.